Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
Ioannis Gounaris's research works | Novartis, Basel and other places
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study | PLOS Medicine
Natasha LeGresley (@tashlegr) / Twitter
7 “Ioannis Gounaris” profil | LinkedIn
Options for the Treatment of Gemcitabine-Resistant Advanced Pancreatic Cancer
Our Publications
Ioannis Gounaris - Executive Medical Director - Merck Group | LinkedIn
Application of ARID1A to murine formalin-fixed... | F1000Research
Ioannis Gounaris's research works | Novartis, Basel and other places
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals
Ovarian clear cell carcinomaâ•flbad endometriosis or bad endometrium?<link href='#fn1'></link><link h
Ioannis Gounaris's research works | Novartis, Basel and other places
Ioannis Gounaris's research works | Novartis, Basel and other places
Ioannis Gounaris's research works | Novartis, Basel and other places
Cambridge City Council on Twitter: "Cambridge market will reopen on Monday (18 January) with traders selling fresh food and produce, plants and cycle services. Full details: https://t.co/A7FZJIn6ki #StaySafeCambridge https://t.co/oeDAb869qx" / Twitter
Ioannis Gounaris's research works | Novartis, Basel and other places
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals
Ovarian clear cell carcinoma—bad endometriosis or bad endometrium? - Gounaris - 2011 - The Journal of Pathology - Wiley Online Library
400+ "Gounaris" profiles | LinkedIn
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. - Abstract - Europe PMC
7 perfiles de «Ioannis Gounaris» | LinkedIn
